Japan's Daiichi Sankyo closing Japan plant with 150 workers

Japan's Daiichi Sankyo, which has been reorganizing its API production as part of a larger cost-cutting initiative, says it will close a plant in Japan where it has 150 employees. In a brief release, the drugmaker said production will stop this month at its API plant in Hiratsuka and that the plant will close by September. It did not say what will happen to employees. Daiichi Sankyo, which has been struggling financially in the face of patent losses, started its manufacturing assessment in 2014, reorganizing its supply chain logistics the same year. It also sold an API plant in Akita to Tokyo-based Alfresa Pharma. Release

Suggested Articles

Mylan recalls one lot of the injectable antibiotic daptomycin after discovering particles in a single-dose vial.

Lupin Pharmaceuticals pulled all lots of its extended-release diabetes drug metformin amid carcinogen contamination concerns.

Novartis and Civica Rx are patterning up to shore up supply of six key generic injectables used in acute care settings in hospitals.